BALANCE: Olezarsen for Familial Chylomicronemia Syndrome

Olezarsen is an investigational drug that tackles triglycerides by blocking the production of apolipoprotein C-III (apoC3). ApoC3 normally hinders the liver’s ability to remove triglycerides from the blood. By reducing apoC3, Olezarsen allows the liver to work more effectively, lowering triglyceride levels. This can significantly reduce the risk of pancreatitis, a dangerous condition caused by high triglyceride levels in the blood.

STEP: Heart Failure in Obesity & Diabetes

Semaglutide benefits obesity-related heart failure in type 2 diabetes, improving symptoms and aiding weight loss. The STEP trial evaluated the effects of semaglutide (Ozempic or Wegovy) 2.4 mg weekly in participants with heart failure, obesity, and type 2 diabetes. Patients received either semaglutide or placebo for 52 weeks.

MAESTRO: First Treatment for NASH

Rezdiffra (Resmetirom), an oral medication targeting the liver and selective for thyroid hormone receptor β, demonstrated promising results. At doses of 80mg and 100mg, it achieved NASH resolution in 25% and 30% of participants, respectively, compared to just 10% in the placebo group.

Novel Drug for Hot Flashes

Menopause is a natural change that occurs in a woman’s life when her ovaries stop producing estrogen and progesterone. Typically, this happens between the ages of 45 and 55. Menopause is generally defined as not having a period for 12 consecutive months. Hot flashes, which affect 80% of women, are one of the most common symptoms of menopause and can significantly disrupt a woman’s life.

Mounjaro Injection for Weight Loss

Obesity significantly impacts a substantial portion of the population in the United States, making it a widespread and pressing health concern. Present statistics indicate that approximately 42% of Americans meet the criteria of having a body mass index (BMI) of 30 or higher, categorizing them as obese.

BrigHTN: Baxdrostat for Resistant Hypertension

Inhibiting aldosterone synthase presents a promising approach to treating hypertension. However, it is key to ensure selective inhibition to avoid compromising cortisol production. Recently, researchers have identified Baxdrostat as a highly selective AS inhibitor that does not interfere with cortisol synthesis. The specificity of Baxdrostat in inhibiting aldosterone synthase over cortisol synthase is 100:1

FIDELIO: Type 2 Diabetes & CKD

Kerendia (Finerenone) is an oral non-steroidal mineralocorticoid receptor (MR) antagonist. Excessive activation of mineralocorticoid receptors can result in hypertension, fluid retention, and cardiovascular harm, all of which have been directly linked to the deterioration of kidney function.

ORION: Gene Silencing, PCSK9 & LDL Cholesterol

Leqvio (Inclisiran) has received FDA approval as an additional therapy to diet and maximally tolerated statin medications for adults diagnosed with either heterozygous familial hypercholesterolemia (HeFH) or severe ASCVD who require further reduction of LDL cholesterol.

Medications for Type 2 Diabetes

It is important to note that the drug recommendations provided here are general and serve only as a guideline. The ultimate clinical decision should consider factors such as medication tolerability, cost, clinical context, glucose control, the patient’s weight loss goals, comorbidities, and patient preferences.